1031 related articles for article (PubMed ID: 24477431)
1. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.
Murphy KE; Gysbers AM; Abbott SK; Tayebi N; Kim WS; Sidransky E; Cooper A; Garner B; Halliday GM
Brain; 2014 Mar; 137(Pt 3):834-48. PubMed ID: 24477431
[TBL] [Abstract][Full Text] [Related]
2. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
Blanz J; Saftig P
J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
[TBL] [Abstract][Full Text] [Related]
3. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels.
Gündner AL; Duran-Pacheco G; Zimmermann S; Ruf I; Moors T; Baumann K; Jagasia R; van de Berg WDJ; Kremer T
Neurobiol Dis; 2019 Jan; 121():205-213. PubMed ID: 30236861
[TBL] [Abstract][Full Text] [Related]
4. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
Wong YC; Krainc D
Mov Disord; 2016 Nov; 31(11):1610-1618. PubMed ID: 27619775
[TBL] [Abstract][Full Text] [Related]
5. Glucocerebrosidase deficits in sporadic Parkinson disease.
Murphy KE; Halliday GM
Autophagy; 2014 Jul; 10(7):1350-1. PubMed ID: 24915553
[TBL] [Abstract][Full Text] [Related]
6. Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.
Albanese F; Mercatelli D; Finetti L; Lamonaca G; Pizzi S; Shimshek DR; Bernacchia G; Morari M
Neurobiol Dis; 2021 Nov; 159():105487. PubMed ID: 34419621
[TBL] [Abstract][Full Text] [Related]
7. Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies.
Xilouri M; Brekk OR; Stefanis L
Mov Disord; 2016 Feb; 31(2):178-92. PubMed ID: 26813776
[TBL] [Abstract][Full Text] [Related]
8. Lysosomal alterations in peripheral blood mononuclear cells of Parkinson's disease patients.
Papagiannakis N; Xilouri M; Koros C; Stamelou M; Antonelou R; Maniati M; Papadimitriou D; Moraitou M; Michelakakis H; Stefanis L
Mov Disord; 2015 Nov; 30(13):1830-4. PubMed ID: 26769460
[TBL] [Abstract][Full Text] [Related]
9. The relationship between glucocerebrosidase mutations and Parkinson disease.
Migdalska-Richards A; Schapira AH
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
[TBL] [Abstract][Full Text] [Related]
10. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease.
Magalhaes J; Gegg ME; Migdalska-Richards A; Doherty MK; Whitfield PD; Schapira AH
Hum Mol Genet; 2016 Aug; 25(16):3432-3445. PubMed ID: 27378698
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of Glucocerebrosidase Dysfunction in Parkinson's Disease.
Chatterjee D; Krainc D
J Mol Biol; 2023 Jun; 435(12):168023. PubMed ID: 36828270
[TBL] [Abstract][Full Text] [Related]
12. Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation.
Galvagnion C; Marlet FR; Cerri S; Schapira AHV; Blandini F; Di Monte DA
Brain; 2022 Apr; 145(3):1038-1051. PubMed ID: 35362022
[TBL] [Abstract][Full Text] [Related]
13. Lysosomal Pathogenesis of Parkinson's Disease: Insights From LRRK2 and GBA1 Rodent Models.
Volta M
Neurotherapeutics; 2023 Jan; 20(1):127-139. PubMed ID: 36085537
[TBL] [Abstract][Full Text] [Related]
14. Neuronopathic GBA1L444P Mutation Accelerates Glucosylsphingosine Levels and Formation of Hippocampal Alpha-Synuclein Inclusions.
Mahoney-Crane CL; Viswanathan M; Russell D; Curtiss RAC; Freire J; Bobba SS; Coyle SD; Kandebo M; Yao L; Wan BL; Hatcher NG; Smith SM; Marcus JN; Volpicelli-Daley LA
J Neurosci; 2023 Jan; 43(3):501-521. PubMed ID: 36639889
[TBL] [Abstract][Full Text] [Related]
15. Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice.
Rocha EM; Smith GA; Park E; Cao H; Graham AR; Brown E; McLean JR; Hayes MA; Beagan J; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Antioxid Redox Signal; 2015 Aug; 23(6):550-64. PubMed ID: 26094487
[TBL] [Abstract][Full Text] [Related]
16. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
McNeill A; Magalhaes J; Shen C; Chau KY; Hughes D; Mehta A; Foltynie T; Cooper JM; Abramov AY; Gegg M; Schapira AH
Brain; 2014 May; 137(Pt 5):1481-95. PubMed ID: 24574503
[TBL] [Abstract][Full Text] [Related]
17. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
[TBL] [Abstract][Full Text] [Related]
18. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
19. Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function.
Kim MJ; Jeon S; Burbulla LF; Krainc D
Hum Mol Genet; 2018 Jun; 27(11):1972-1988. PubMed ID: 29579237
[TBL] [Abstract][Full Text] [Related]
20. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.
Kumar M; Srikanth MP; Deleidi M; Hallett PJ; Isacson O; Feldman RA
Hum Mol Genet; 2023 May; 32(11):1888-1900. PubMed ID: 36752535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
